Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trial

Basit Öğe Kaydı
dc.authoridBondarenko, Igor/0000-0002-7071-2471
dc.authorwosidBondarenko, Igor/U-5156-2017
dc.contributor.authorHo, G. F.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorKilickap, S.
dc.contributor.authorSezer, A.
dc.contributor.authorGumus, M.
dc.contributor.authorBondarenko, I.
dc.contributor.authorGogishvili, M.
dc.date.accessioned2024-06-12T11:20:23Z
dc.date.available2024-06-12T11:20:23Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.descriptionESMO Asia Congress -- DEC 02-04, 2022 -- Singapore, SINGAPOREen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipEuropean Soc Med Oncolen_US
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc.; Sanofien_US
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc., and Sanofi.en_US
dc.identifier.doi10.1016/j.annonc.2022.10.366
dc.identifier.endpageS1571en_US
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.startpageS1570en_US
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2022.10.366
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25584
dc.identifier.volume33en_US
dc.identifier.wosWOS:000897943700333en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofAnnals Of Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[No Keywords]en_US
dc.titleThree years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trialen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu